Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of melatonin on proteinuria, inflammation, and oxidative stress in chronic kidney disease
IRCT20160412027346N12Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of melatonin in chronic kidney disease (CKD), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Proteinuria change, Inflammatory markers and 1 more. Started Jan 2025; status: completed.
02
Drugs
melatonin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20160412027346N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160412027346N12.